The new capability will enable clinicians to quantify the density of blood flow in the retina, the light-sensitive portion of the eye.

The AngioVue Imaging System incarnates OCTA technology, which deploys light rays to form detailed three-dimensional images of the retina, allowing physicians to quickly visualize the anatomic structures and abnormalities.

The system is said to acquire a single image in less than three seconds and it can replace the current angiography imaging standard, fluorescein angiography (FA), in some cases with multiple advantages.

Optovue founder and CEO Jay Wei said: "Providing clinicians with the ability to quantify blood flow in the retina should allow for earlier and more individualized treatment, without the need or cost of repeated dye injections.

"We are very pleased with the adoption and utilization of the AngioVue System since its introduction last year, and we expect AngioAnalytics to further its momentum."